NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of Receptos, Inc. (“Receptos” or the “Company”) (NASDAQ:RCPT) concerning the proposed acquisition of the Company by Celgene Corporation. Pursuant to the terms of the definitive agreement, Receptos stockholders will receive $232.00 in cash for each share of Receptos common stock they own, in a transaction valued at approximately $7.2 billion. The investigation concerns whether the Rece